Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma

Patients with recurrent glioblastoma achieving response to bevacizumab combined with chemotherapy have clinical improvement and prolonged survival. High gene expression of angiotensinogen (AGT) is associated with a poor bevacizumab response. Because AGT expression is epigenetically regulated, we aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Urup, Thomas, Gillberg, Linn, Kaastrup, Katja, Lü, Maya Jeje Schuang, Michaelsen, Signe Regner, Andrée Larsen, Vibeke, Christensen, Ib Jarle, Broholm, Helle, Lassen, Ulrik, Grønbæk, Kirsten, Poulsen, Hans Skovgaard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7191184/
https://www.ncbi.nlm.nih.gov/pubmed/32133779
http://dx.doi.org/10.1002/1878-0261.12660

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7191184/
https://www.ncbi.nlm.nih.gov/pubmed/32133779
http://dx.doi.org/10.1002/1878-0261.12660

Ejemplares similares